证券代码：688363 证券简称：华熙生物 公告编号：2025-024 华熙生物科技股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司" "华熙生物"）于近日收到 上海证券交易所科创板公司管理部下发的《关于华熙生物科技股份有限公司 （上证科创公函【2025】0245 号，以 下简称" 《问询函》"）。公司对上述《问询函》提到的问题高度重视，公司与致 同会计师事务所（特殊普通合伙） （以下简称"年审会计师"或"会计师"）对 《问询函》所涉及的问题进行了审慎核查，现就相关问题回复如下： 问题一、关于公司主营业务和经营业绩。年报披露，2024 年度，公司营 业收入 53.71 亿元，同比下滑 11.61%，其中功能性护肤品业务收入同比下滑 肤品业务收入下滑、期间费用增加及资产减值损失等因素影响，公司实现净利 润 1.74 亿元，同比下滑 70.59%。公司近年从产品、渠道、组织、品牌等方面 进行调整以夯实业务基础，20 ...

Group 1 - The core point of the news is that Zhong Shanshan, the actual controller of Jiangsu Jinbo Biological Pharmaceutical Co., Ltd., has decided to invest 3.4 billion yuan in the company through his strategic investor, Yangshengtang Co., Ltd. [1] - The total transaction amount for the share transfer is 3.4 billion yuan, with Zhong Shanshan becoming the second-largest shareholder of Jinbo Biological after the investment [1][3] - Jinbo Biological's core business focuses on high-end implantable medical devices made from recombinant human collagen, primarily used in aesthetic medicine and surgical repairs [4] Group 2 - Jinbo Biological's sales of its core product "Wei Yimei" doubled in 2024, generating revenue of 1.443 billion yuan and a net profit of approximately 732 million yuan, with a gross margin of 92.02% [4] - The company has faced challenges with channel partners, including accusations against Xinyang and Meituan for unauthorized promotions and pricing issues [5] - The partnership with Yangshengtang is expected to leverage Zhong Shanshan's extensive retail network of 3 million terminals to enhance brand promotion and market expansion [5] Group 3 - The vaccine industry is currently undergoing a painful transition, with many companies, including Wantai Biological Pharmacy, seeking new growth avenues beyond traditional models [7] - Companies like Zhifei Biological and Watson Bio are diversifying their business by entering new therapeutic areas, such as metabolic diseases and gut microbiome therapies, in response to declining vaccine sales [7][8] - Watson Bio has signed an exclusive licensing agreement to develop and commercialize core microbiome analysis and targeted transplantation technologies, indicating a strategic shift towards microbiome health [9]

Core Viewpoint - The article discusses the rise and influence of the "Putian system" in the medical aesthetics industry, highlighting the complex relationships and business strategies employed by four prominent families within this sector [1][2][3]. Group 1: Overview of the Putian System in Medical Aesthetics - The Putian system has significant involvement in various branches of private healthcare, particularly in the lucrative medical aesthetics sector [1]. - The push for popularizing conventional aesthetic procedures like breast augmentation, liposuction, and facial surgeries was initially driven by the "Putian system" [2]. - Four major families dominate the Putian medical aesthetics landscape: the Chen Jinxi family of Meilai, the Chen Guoxing and Chen Guoxiong brothers of Yixing, the Zhan Zongyang family of Weilin, and the Huang Defeng family, formerly of Meilian [3][4]. Group 2: Historical Context and Development - The origins of these families can be traced back to Chen Deliang, the "founding father" of the Putian medical system, who established a significant medical faction through low-cost treatments [5][6]. - The early expansion model involved setting up clinics near transportation hubs and using street advertising to attract patients, leading to a "point-based expansion + advertising" strategy [7]. - The Putian system officially entered the medical aesthetics industry in the first decade of the 21st century, motivated by the potential for high profits [8]. Group 3: Business Strategies and Operations - The Putian system merchants adapted and expanded their medical model, focusing on aggressive marketing, self-branded products, and deep ties with industry associations [9]. - The four families have seen significant growth, although many have begun to withdraw from the increasingly regulated medical aesthetics market [10]. Group 4: Case Studies of Major Families - **Meilai (Chen Jinxi Family)**: Meilai has grown to encompass 108 member enterprises and employs over 12,600 people, offering a wide range of aesthetic services [17]. The family has faced controversies regarding its advertising practices and has been involved in numerous administrative penalties [25][24]. - **Yixing (Chen Guoxing Family)**: This family has established a significant presence in the medical aesthetics sector, with Yixing being ranked second among private medical aesthetics chains in China as of 2017 [45]. However, they faced challenges in their IPO attempts due to concerns over compliance and sustainability [48][49]. - **Weilin (Zhan Zongyang Family)**: Weilin has positioned itself as an international brand and has been involved in the medical aesthetics installment loan market, which has raised regulatory concerns [75][86]. - **Meilian (Huang Defeng Family)**: This family has divested from Meilian and has seen a decline in its operations, with the company facing multiple medical disputes and administrative challenges [93][102]. Group 5: Industry Trends and Future Outlook - The medical aesthetics market is entering a phase of slower growth and increased regulation, which may limit the previously unchecked expansion of the Putian system [106]. - The article suggests that the era of the "four families" is coming to an end as they face increasing scrutiny and operational challenges, marking a significant shift in the industry landscape [107][108].

瑞财经 吴文婷钟睒睒又有新动作。 近日，锦波生物宣布两笔交易。其中一笔交易为，锦波生物拟以引入战略投资者方式，向养生堂发行不超过717.57万股，占其发行前总股本的6.24%，募资 金额不超过20亿元。若成功实施，这将是北交所史上最大金额的现金定增。 股权穿透显示，受让方养生堂和杭州久视的实控人均为钟睒睒。钟睒睒持有养生堂98.38%股权；而养生堂持有杭州久视99.75%股权。换言之，钟睒睒34亿 元投向了锦波生物。 在钟睒睒出手后，锦波生物股价大涨，总市值突破400亿。截至发稿时，其报350.55元，涨0.5%，总市值约403.36亿元。 | 锦波生物(BJ:832982) 可融资 可卖空 | | | | | --- | --- | --- | --- | | ¥350.55 +1.75 +0.50% | | | 交易中 | | 最高:359.80 | 今开:347.01 | 成交量:8127手 | | | 最低:346.00 | 昨收:348.80 | 成交额:2.86亿 | 4 | | 52周最高: 451.74 | 市盈率(TTM): -- | 股息(TTM): 2.31 | 元 | | 52周最低: ...

Core Viewpoint - The strategic investment by Zhong Shanshan in Jinbo Biological is seen as a significant move into the collagen protein sector, indicating confidence in the company's growth potential and the broader medical beauty industry [2][8]. Group 1: Investment Details - Jinbo Biological announced the introduction of strategic investors, raising a total of 3.4 billion yuan, with 2 billion yuan allocated to the issuance of shares to Yangshengtang [2][3]. - Zhong Shanshan, through Yangshengtang and Hangzhou Jiushi, will hold a combined 10.58% stake in Jinbo Biological after the transaction [5][6]. - The investment aims to enhance Jinbo Biological's production capabilities and market reach, leveraging Yangshengtang's resources [10]. Group 2: Company Performance - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, marking an 84.92% year-on-year increase, with a net profit of 732 million yuan, up 144.27% [15]. - The company boasts a high gross margin of 92.02% and a net profit margin of 50.68%, reflecting strong profitability [15]. - Jinbo Biological is recognized as a leader in the recombinant human collagen field, having achieved significant technological breakthroughs [15]. Group 3: Market Context - The medical beauty sector is becoming increasingly competitive, with Jinbo Biological facing challenges from rivals like Juzhi Biological and Marubi [11]. - Yangshengtang's recent performance has been lackluster, with its main companies, Nongfu Spring and Wantai Biological, showing minimal revenue growth [13][14]. - The investment by Zhong Shanshan may be a strategic move to diversify and seek new growth avenues amid stagnation in his existing businesses [13][16].

Core Insights - New Oxygen has officially become the largest light medical beauty chain brand in China with 31 operational stores as of June 2025, marking a significant milestone in its strategic transformation to New Oxygen 2.0 [1][4] - The chain business revenue has become the largest income source for New Oxygen, indicating a successful shift from a transaction platform to an integrated industry platform [1][4] Group 1: Business Growth and Strategy - Since the opening of its first self-operated clinic in May 2023, New Oxygen has achieved a remarkable growth of 370 times in customer visits, from 54 to over 20,000 in just 24 months, relying solely on natural foot traffic without the New Oxygen app [2][6][7] - The company has built a comprehensive supply chain through acquisitions and exclusive partnerships, establishing a full-chain industry layout from equipment to consumables [2] - New Oxygen has assembled a team of over 120 full-time doctors, with a rigorous training system and a four-tier service structure, achieving an average of 3,048 procedures per doctor annually, significantly above the industry average [2][13] Group 2: Trust and Customer Satisfaction - New Oxygen addresses the long-standing trust crisis in the medical beauty industry by prioritizing delivery over marketing, ensuring high-quality service and transparency [3][10] - The company has reduced customer acquisition costs to below 10%, compared to 30%-50% in traditional institutions, fostering a cycle of high satisfaction and repeat purchases, with customer satisfaction consistently at 4.98 out of 5 and a repeat purchase rate exceeding 60% [3][9] - By adopting a model similar to "胖东来," New Oxygen provides decision-making support tools that enhance transparency and allow customers to make informed choices, thereby improving trust [3][16]

2025.06. 30 本文字数：2730，阅读时长大约4.5分钟 "把三个手指握住助推杆向后回抽，小拇指向前推药，像打除皱、瘦脸、瘦肩、瘦腿，我们就这样拿 针，这些技术其实都是 比较简单 的。你通过 一次学习 之后，现场 看一个实操 ，回家立马 捡起注 射器就能干 。 " 这段轻描淡写的"贯口"令人毛骨悚然。它不是笑话，而是非法医美速成班的培训师在教学。 总台新闻频道6月29日播出记者暗访调查报道，在非法医美速成培训班通过三天培训，"零基础"的学 员摇身一变就能成为"医美从业者"。 就在刚刚结束的周末，这家非法举办医美速成班的培训机构在全国8座城市还在同时开班授课。 非法速成、多地同时开班 声称"日收入无上限" 6月28日上午，记者依照上课地址，来到广西南宁西乡塘区一家酒店的会议室，大约有20多人，其中 还有第二次来参加课程的老学员。在正式上课之前，一名自称夏老师的工作人员向大家介绍所在机构 的规模和权威性。 医美速成培训班培训师表示，"我们公司在美业教培已经做了16年，我们在全国一共有32所学校。全 国一线城市，包括现在有的二线城市都有我们的校区。我们这十多年已经帮助了10万家的美业人才 拿到了结果。" ...

Core Viewpoint - The investment by Zhong Shanshan in Jinbo Biological is a strategic move to capitalize on the growth opportunities in the recombinant collagen market, which is expected to see significant expansion in the coming years [7][8]. Investment Details - Zhong Shanshan plans to fully subscribe to Jinbo Biological's private placement fundraising of up to 2 billion yuan through his company, Yangshengtang [1][3]. - Additionally, he will acquire 5% of Jinbo Biological's shares from the actual controller Yang Xia for 1.403 billion yuan [3][4]. - After the transactions, Yangshengtang and Hangzhou Jiushi will hold 5.87% and 4.71% of Jinbo Biological, respectively, allowing Zhong to indirectly control 10.58% of the company [4]. Financial Performance - Jinbo Biological's medical device segment has a gross margin of 95.03%, surpassing that of Kweichow Moutai [5][6]. - The company reported revenues of approximately 3.9 billion yuan, 7.8 billion yuan, and 14.43 billion yuan for the years 2022, 2023, and 2024, respectively, with corresponding net profits of about 1.09 billion yuan, 3 billion yuan, and 7.32 billion yuan [6]. - The stock price of Jinbo Biological has seen a significant increase, with a cumulative rise of 118.33% from January 2 to June 27, 2024, making it the highest-priced stock on the Beijing Stock Exchange [6]. Market Outlook - The recombinant collagen product market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 and 219.38 billion yuan by 2030 [8]. - Despite the growth, there are concerns about increased competition in the medical aesthetics sector, highlighted by recent disputes between major players in the industry [8]. Strategic Implications - The investment is seen as a significant step for Zhong Shanshan to expand his footprint in the high-growth health sector, potentially leading to substantial returns [7]. - Jinbo Biological aims to leverage the resources and expertise of Yangshengtang to enhance its product development, industrial production, and market strategies [4][7].

Core Viewpoint - The article discusses the strategic investment by Zhong Shanshan in Jinbo Biotechnology, a company specializing in recombinant collagen products, highlighting the potential for growth in the medical beauty industry and the collaboration's expected synergies [2][4][6]. Group 1: Investment Details - Jinbo Biotechnology announced a strategic investment from Yangshengtang, with a total transaction amount reaching 3.4 billion yuan [1][4]. - The company plans to issue up to 717.57 million shares, accounting for 6.24% of its pre-issue total share capital, aiming to raise no more than 2 billion yuan, which would be the largest cash capital increase in the history of the Beijing Stock Exchange [4]. - Yang Xia, the founder of Jinbo Biotechnology, transferred 575.33 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4][7]. Group 2: Company Background - Jinbo Biotechnology, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [2][12]. - The company’s main products include various terminal medical devices and functional skincare products based on type A recombinant human collagen [12][14]. - Jinbo Biotechnology's core product, the injectable recombinant type III human collagen, has been widely adopted, with over 2 million applications across approximately 4,000 medical institutions [12][14]. Group 3: Market Dynamics - The medical beauty industry is characterized by high profitability, with Jinbo Biotechnology reporting a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, and a net profit of 732 million yuan, up over 140% [14]. - The gross margin of Jinbo Biotechnology reached 92%, surpassing that of leading companies like Kweichow Moutai [14]. - The article notes that the demand for recombinant collagen is growing, with significant consumer interest reflected in social media discussions and product popularity [17][19]. Group 4: Future Prospects - The collaboration between Jinbo Biotechnology and Yangshengtang is expected to enhance product development, industrial production, and market strategy, aiming to create a large-scale industrial production system [6][12]. - The investment is seen as a strategic move to strengthen Jinbo Biotechnology's position in a competitive market, where it currently faces challenges due to its smaller size and limited financial resources [6][12].

Core Viewpoint - The rise of male consumers, particularly those born in the 1990s, is significantly impacting the medical beauty market in China, driven by changing perceptions of masculinity and beauty standards [2][5][10]. Group 1: Market Trends - The medical beauty market in China is experiencing a shift, with a notable increase in male users, particularly among those born in the 1990s, who are now seen as a key demographic for growth [2][9]. - In the past year, the percentage of male customers visiting medical beauty institutions has risen from 4.9% to 7.3%, indicating a growing acceptance and demand for medical beauty services among men [2][3]. - The average spending per male customer is approximately 2.75 times higher than that of female customers, highlighting the potential profitability of targeting male consumers [10][11]. Group 2: Consumer Behavior - Male consumers, especially those in their 20s to 40s, prefer subtle and natural-looking enhancements, with a focus on skin care and anti-aging treatments rather than more invasive procedures [3][6]. - The primary motivations for male medical beauty users include improving personal image for career and dating prospects, rather than purely aesthetic reasons [6][8]. - Social media has played a crucial role in shaping the beauty standards and consumption habits of younger male consumers, who are more open to exploring medical beauty options [7][9]. Group 3: Industry Challenges - Despite the growing market, the medical beauty industry faces challenges such as a lack of trust and awareness among potential male consumers, which hinders market penetration [9][12]. - The industry is also grappling with rising costs of materials and new regulations that impact marketing strategies, making it essential for brands to find innovative ways to attract male customers [9][10]. - Education and awareness campaigns are necessary to inform male consumers about available treatments and to alleviate any stigma associated with medical beauty procedures [12][16]. Group 4: Future Outlook - The male medical beauty market is expected to grow significantly, with projections indicating that by 2025, the market size could exceed 500 billion yuan, with male consumers accounting for over 30% of the market [9][16]. - The next three to five years are seen as a critical window for the male medical beauty sector to expand, with potential for tailored services and products designed specifically for male consumers [16]. - As the market matures, there will likely be a diversification of services, including specialized offerings in hair restoration and body sculpting, catering to the unique needs of male clients [15][16].